home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630666.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
3KB
|
44 lines
Document 0666
DOCN M9630666
TI Prolonged survival of mice with glioma injected intracerebrally with
double cytokine-secreting cells.
DT 9603
AU Lichtor T; Glick RP; Kim TS; Hand R; Cohen EP; Division of Neurosurgery,
Cook County Hospital, Chicago,; Illinois, USA.
SO J Neurosurg. 1995 Dec;83(6):1038-44. Unique Identifier : AIDSLINE
MED/96086871
AB A novel approach toward the treatment of glioma was developed in a
murine model. The genes for both interleukin-2 (IL-2) and
interferon-gamma (IFN-gamma) were first transfected into a mouse
fibroblast cell line that expresses defined major histocompatibility
complex (MHC) determinants (H-2k). The double cytokine-secreting cells
were then cotransplanted intracerebrally with the Gl261 murine glioma
cell line into syngeneic C57BL/6 mice (H-2b) whose cells differed at the
MHC from the cellular immunogen. The results indicate that the survival
of mice with glioma injected with the cytokine-secreting allogeneic
cells was significantly prolonged, relative to the survival of mice
receiving equivalent numbers of glioma cells alone. Using a standard
51Cr-release assay, the specific release of isotope from labeled Gl261
cells coincubated with spleen cells from mice injected intracerebrally
with the glioma cells and the cytokine-secreting fibroblasts was
significantly higher than the release of isotope from glioma cells
coincubated with spleen cells from nonimmunized mice. The cellular
antiglioma response was mediated by natural killer/lymphokine-activated
killer and Lyt-2.2+ (CD8+) cells. The increased survival of mice with
glioma and the specific immunocytotoxic responses after immunization
with fibroblasts modified to secrete both IL-2 and IFN-gamma indicate
the potential of an immunotherapeutic approach to gliomas with
cytokine-secreting cells.
DE Animal Brain Neoplasms/MORTALITY/*THERAPY Cell Line Cytotoxicity,
Immunologic CD8-Positive T-Lymphocytes/IMMUNOLOGY Disease Models,
Animal Female Fibroblasts/*SECRETION/TRANSPLANTATION
Glioma/MORTALITY/*THERAPY Interferon Type II/*SECRETION/THERAPEUTIC USE
Interleukin-2/*SECRETION/THERAPEUTIC USE Killer Cells,
Lymphokine-Activated/IMMUNOLOGY Killer Cells, Natural/IMMUNOLOGY Mice
Mice, Inbred C57BL Spleen/CYTOLOGY/IMMUNOLOGY Support, U.S. Gov't,
P.H.S. Time Factors Transfection JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).